DCVC, a venture capital firm, led a $13m funding round in Shennon Biotechnologies, a biotech company, with participation from Foundation Capital and AV8. “At ShennonBio, our interdisciplinary team of engineers and scientists have developed a single-cell screening platform that can identify rare effector T cells against specific antigens at ultrahigh throughput by measuring functional secretion. While current approaches take weeks to isolate a T cell target, our technology platform can do this in a matter of hours, with more precision, which ultimately increases the overall probability of generating a curative treatment in a shorter period of time for cancer patients. We’re thrilled to have the support of such a great group of investors and be able to scale up our target discovery efforts with this funding,” Li Sun, Shennon Biotechnologies CEO and Founder.